H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $40 from $36 and keeps a Buy rating on the shares. The firm believes the Merus (MRUS) acquisition bolsters Genmab’s late-stage pipeline. Petosemtamab’s market opportunity in head and neck cancer alone could exceed $3B annually, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab A/S Updates Articles of Association to Enhance Growth Strategy
- Genmab’s Strategic Acquisitions and Promising Pipeline Drive Buy Rating
- Genmab’s Strategic Acquisition of MRUS: A Long-Term Positive Move Enhancing Pipeline and Growth Potential
- Genmab price target raised to $34 from $32 at Leerink
- Video: Merus jumps after deal to be bought, MoonLake sinks after trial data